Laura Pina Vegas

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 21

Top Topics

Health Insurance

Top Venues

The British journal of dermatology

Rheumatology (Oxford, England)

Annals of the rheumatic diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS). RMD open 10 (1) (2024)
Laura Pina Vegas, Jérôme Drouin, Alain Weill, Rosemary Dray-Spira
Pregnancy outcomes in women with rheumatoid arthritis: an 11-year French nationwide study. RMD open 10 (1) (2024)
Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS). RMD open 10 (1) (2024)
Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS). RMD open 10 (1) (2024)
Laura Pina Vegas, Siham Iggui, Emilie Sbidian, Pascal Claudepierre
Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS). RMD open 10 (3) (2024)
Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS). RMD open 10 (1) (2024)
Laura Pina Vegas, Jérôme Drouin, Alain Weill, Rosemary Dray-Spira
Pregnancy outcomes in women with rheumatoid arthritis: an 11-year French nationwide study. RMD open 10 (1) (2024)
Laura Pina Vegas, Jérôme Drouin, Alain Weill, Rosemary Dray-Spira
Pregnancy outcomes in women with rheumatoid arthritis: an 11-year French nationwide study. RMD open 10 (1) (2024)
Laura Pina Vegas, Jérôme Drouin, Alain Weill, Rosemary Dray-Spira
Pregnancy outcomes in women with rheumatoid arthritis: an 11-year French nationwide study. RMD open 10 (1) (2024)
Laura Pina Vegas, Pascal Claudepierre
Trajectories of comorbidities in patients with psoriasis: a question to be answered. The British journal of dermatology 188 (3) (2023)
Laura Pina Vegas, Laetitia Penso, Emilie Sbidian, Pascal Claudepierre
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD open 9 (4) (2023)
Laura Pina Vegas, Laetitia Penso, Emilie Sbidian, Pascal Claudepierre
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD open 9 (4) (2023)
Laura Pina Vegas, Pascal Claudepierre
Comparison of biologics in psoriatic arthritis: an important clinical issue. Rheumatology (Oxford, England) (2023)
Laura Pina Vegas, Laetitia Penso, Emilie Sbidian, Pascal Claudepierre
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD open 9 (4) (2023)
Laura Pina Vegas, Léa Hoisnard, Léa Bastard, Emilie Sbidian, Pascal Claudepierre
Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS). RMD open 8 (2) (2023)
Laura Pina Vegas, Pascal Claudepierre
Trajectories of comorbidities in patients with psoriasis: a question to be answered. The British journal of dermatology 188 (3) (2023)
Laura Pina Vegas, Laetitia Penso, Emilie Sbidian, Pascal Claudepierre
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD open 9 (4) (2023)
Laura Pina Vegas, Léa Hoisnard, Léa Bastard, Emilie Sbidian, Pascal Claudepierre
Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS). RMD open 8 (2) (2023)
Laura Pina Vegas, Pascal Claudepierre, Emilie Sbidian
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply. Rheumatology (Oxford, England) 61 (8) (2022)
Laura Pina Vegas, Pascal Claudepierre
Trajectories of comorbidities in patients with psoriasis: a question to be answered. The British journal of dermatology (2022)
Lea Hoisnard, Laura Pina Vegas, Rosemay Dray-Spira, Alain Weill, Mahmoud Zureik, Emilie Sbidian
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Annals of the rheumatic diseases (2022)